New lung cancer cocktail trial aims to shrink tumors
NCT ID NCT07622186
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a new drug called SKB571 combined with other cancer medicines in 150 people with non-small cell lung cancer. The goal is to see if the combination can shrink tumors and control the disease. Participants will receive the drugs by injection or mouth, and researchers will monitor side effects and how long the benefits last.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SKB571 (injection) combined with osimertinib, furmonertinib, carboplatin, cisplatin, or pembrolizumab
- What this could lead to
- If it works, this could offer a new combination treatment option to control non-small cell lung cancer and slow its progression.
- What could go wrong
- This is an early phase 2 trial, so it's not yet proven to work. Side effects from the drug combinations could be serious, and the results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dongguan People's Hospital
Dongguan, Guangdong, 523018, China
-
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, 350014, China
-
Guangxi Medical University Affiliated Tumor Hospital
Nanning, Guangxi, 530021, China
-
Guangzhou Medical University First Affiliated Hospital
Guangzhou, Guangdong, 510120, China
-
Guilin Medical University First Affiliated Hospital
Guilin, Guangxi, 541001, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450008, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
-
Jiangxi Cancer Hospital
Nanchang, Jiangxi, 330029, China
-
Jilin Cancer Hospital
Changchun, Jilin, 130012, China
-
Peking University Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
-
Shanxi Cancer Hospital
Taiyuan, Shanxi, 030013, China
-
Shengjing Hospital of China Medical University
Shenyang, Liaoning, 110004, China
-
Sichuan Cancer Hospital & Institute
Chengdu, Sichuan, 610041, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of Xi'an Jiao Tong University
Xi’an, Shanxi, 710061, China
-
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, 361003, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China
-
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, 300060, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
-
Xiangyang Central Hospital
Xiangyang, Hubei, 441021, China
-
Xinjiang Medical University Affiliated Tumor Hospital
Ürümqi, Xinjiang Uygur Autonomous Region, 830011, China
-
Xinqiao Hospital of Army Medical University
Chongqing, Chongqing Municipality, 400037, China
-
Yunnan Cancer Hospital
Kunming, Yunnan, 650118, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?